No Data
No Data
Express News | HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $102 Price Target
Viking Therapeutics Analyst Ratings
Positive Outlook for Viking Therapeutics: Strong Trial Enrollment and Upcoming Milestones Suggest Upside Potential
Express News | Viking Therapeutics Inc: Expects to Report Data From Study in Second Half of 2025.
Express News | Viking Therapeutics Announces Completion of Enrollment in Phase 2 Venture-Oral Dosing Trial of Vk2735 Tablet Formulation in Patients With Obesity
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients With Obesity